Susceptibility of Gram-negative bacteria to isepamicin: a systematic review

Abstract

We sought to review the potential role of isepamicin against infections with contemporary Gram-negative bacteria. We searched PubMed and Scopus databases to identify relevant microbiological and clinical studies published between 2000 and 2010, and we retrieved 11 and three studies, respectively. A total of 4901 isolates were examined in the in vitro studies. Isepamicin had higher in vitro activity compared with amikacin in four studies, was as active as amikacin in six studies and in the remaining study both were inactive. Regarding specifically the studies that included multidrug-resistant bacteria, isepamicin appeared superior to amikacin in two studies, as active as amikacin in one study and both did not exhibit activity in one study. In the clinical studies, isepamicin was as active as amikacin for the treatment of 55 children with urinary tract infections. In conclusion, isepamicin might be active in vitro against Gram-negative bacteria with resistance to amikacin and other aminoglycosides.

Exploration of Antibiotic Activity of Aminoglycosides, in Particular Ribostamycin Alone and in Combination With Ethylenediaminetetraacetic Acid Against Pathogenic Bacteria

“…Netilmicin is a semisynthetic aminoglycoside, which shows similar activity as gentamicin with less toxicity (Miller et al, 1976). Isepamicin exhibits similar antibiotic spectrum as amikacin and is active against various Gram-negative bacteria (Falagas et al, 2012). Ribostamycin is a natural aminoglycoside, which has a broad-spectrum antibiotic activity (Horibe et al, 2001).…”

In Vitro Antimicrobial Susceptibility to Isepamicin of 6,296 Enterobacteriaceae Clinical Isolates Collected at a Tertiary Care University Hospital in Greece

“…There are differences in the patterns of resistance to aminoglycosides between different regions and in different time periods, which relate mainly to the selection pressure from the use of different members of this class (31). Nevertheless, the rather limited relevant published data available from different countries (mainly those in which isepamicin was available for clinical use) support the idea that isepamicin has very good in vitro activity against Gram-negative pathogens compared to other commonly used aminoglycosides (12). The prevalence of resistance to a new aminoglycoside can increase rather quickly, depending on the consumption of the drug (19).…”

“…It has been available in only a limited number of countries (including Japan, South Korea, China, and other Asian countries as well as certain European countries like Belgium and Italy) (27,38). The susceptibility of Gram-negative bacterial isolates to isepamicin can be higher than that to amikacin (12). In a selection of 65 of carbapenem-resistant Enterobacteriaceae strains, other than NDM-1 producers, 63 were found to be susceptible to isepamicin (27).…”

Recent progress on the development of antibiotics from the genus Micromonospora

“…Isepamicin is a semi-synthetic derivative of gentamicin B, which possesses a high level of stability to aminoglycoside inactivating enzymes and low levels of toxicity to the kidney and inner ear. In addition, isepamicinis active against Gram-negative bacteria with resistance to amikacin and other aminoglycosides [335][336][337]. Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomicin has similar activity as for gentamicin but less toxic [338].…”